Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
The goal of cancer immunotherapy is to establish new or boost pre-existing anticancer immune responses that eradicate malignant cells while generating immunological memory to prevent disease relapse. Over the past few years, immunomodulatory monoclonal antibodies (mAbs) that block co-inhibitory rece...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
29 Sep 2017
|
| In: |
OncoImmunology
Year: 2017, Jahrgang: 6, Heft: 12 |
| ISSN: | 2162-402X |
| DOI: | 10.1080/2162402X.2017.1371896 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1080/2162402X.2017.1371896 Verlag, Volltext: https://doi.org/10.1080/2162402X.2017.1371896 
|
| Verfasserangaben: | Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Kroemer, Aura Muntasell, Lorenzo Galluzzi |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1571716637 | ||
| 003 | DE-627 | ||
| 005 | 20230426124232.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180405s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/2162402X.2017.1371896 |2 doi | |
| 035 | |a (DE-627)1571716637 | ||
| 035 | |a (DE-576)501716637 | ||
| 035 | |a (DE-599)BSZ501716637 | ||
| 035 | |a (OCoLC)1341001587 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Cabo, Mariona |e VerfasserIn |0 (DE-588)1155542835 |0 (DE-627)1017809658 |0 (DE-576)501718613 |4 aut | |
| 245 | 1 | 0 | |a Trial Watch |b Immunostimulatory monoclonal antibodies for oncological indications |c Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Kroemer, Aura Muntasell, Lorenzo Galluzzi |
| 264 | 1 | |c 29 Sep 2017 | |
| 300 | |a 16 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.04.2018 | ||
| 520 | |a The goal of cancer immunotherapy is to establish new or boost pre-existing anticancer immune responses that eradicate malignant cells while generating immunological memory to prevent disease relapse. Over the past few years, immunomodulatory monoclonal antibodies (mAbs) that block co-inhibitory receptors on immune effectors cells - such as cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PDCD1, best known as PD-1) - or their ligands - such as CD274 (best known as PD-L1) - have proven very successful in this sense. As a consequence, many of such immune checkpoint blockers (ICBs) have already entered the clinical practice for various oncological indications. Considerable attention is currently being attracted by a second group of immunomodulatory mAbs, which are conceived to activate co-stimulatory receptors on immune effector cells. Here, we discuss the mechanisms of action of these immunostimulatory mAbs and summarize recent progress in their preclinical and clinical development. | ||
| 650 | 4 | |a CD137 | |
| 650 | 4 | |a CD40 | |
| 650 | 4 | |a GITR | |
| 650 | 4 | |a ICOS | |
| 650 | 4 | |a OX40 | |
| 650 | 4 | |a PD-1 | |
| 700 | 1 | |a Offringa, Rienk |e VerfasserIn |0 (DE-588)1066807485 |0 (DE-627)817963391 |0 (DE-576)426161424 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t OncoImmunology |d Abingdon : Taylor & Franics, 2012 |g 6(2017,12) Artikel-Nummer e1371896, 16 Seiten |h Online-Ressource |w (DE-627)683365428 |w (DE-600)2645309-5 |w (DE-576)356728366 |x 2162-402X |7 nnas |a Trial Watch Immunostimulatory monoclonal antibodies for oncological indications |
| 773 | 1 | 8 | |g volume:6 |g year:2017 |g number:12 |g extent:16 |a Trial Watch Immunostimulatory monoclonal antibodies for oncological indications |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/2162402X.2017.1371896 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1080/2162402X.2017.1371896 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180405 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1066807485 |a Offringa, Rienk |m 1066807485:Offringa, Rienk |d 910000 |d 910200 |e 910000PO1066807485 |e 910200PO1066807485 |k 0/910000/ |k 1/910000/910200/ |p 2 | ||
| 999 | |a KXP-PPN1571716637 |e 3004964546 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"29 Sep 2017","dateIssuedKey":"2017"}],"person":[{"given":"Mariona","family":"Cabo","role":"aut","display":"Cabo, Mariona"},{"family":"Offringa","role":"aut","display":"Offringa, Rienk","given":"Rienk"}],"id":{"eki":["1571716637"],"doi":["10.1080/2162402X.2017.1371896"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Kroemer, Aura Muntasell, Lorenzo Galluzzi"]},"title":[{"title":"Trial Watch","title_sort":"Trial Watch","subtitle":"Immunostimulatory monoclonal antibodies for oncological indications"}],"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"Onco Immunology"}],"note":["Gesehen am 13.12.2022"],"physDesc":[{"extent":"Online-Ressource"}],"recId":"683365428","title":[{"title_sort":"OncoImmunology","title":"OncoImmunology"}],"disp":"Trial Watch Immunostimulatory monoclonal antibodies for oncological indicationsOncoImmunology","part":{"volume":"6","extent":"16","text":"6(2017,12) Artikel-Nummer e1371896, 16 Seiten","issue":"12","year":"2017"},"id":{"zdb":["2645309-5"],"issn":["2162-402X"],"eki":["683365428"]},"origin":[{"publisher":"Taylor & Franics ; Landes Bioscience","publisherPlace":"Abingdon ; Austin, Tex.","dateIssuedKey":"2012","dateIssuedDisp":"2012-"}],"language":["eng"],"pubHistory":["1.2012 -"]}],"recId":"1571716637","physDesc":[{"extent":"16 S."}],"note":["Gesehen am 05.04.2018"],"language":["eng"]} | ||
| SRT | |a CABOMARIONTRIALWATCH2920 | ||